Mental health services develop to meet societal needs and have largely been reactive to demand, not proactive in deciding how they might best reduce the burden of disease. The new wave of mental health surveys (Reference KesslerKessler, 1999; Reference Andrews, Henderson and HallAndrews et al, 2001) has determined how many people had which mental disorder(s), how disabled they were, what services they used and the barriers to better service use. Accounts of services used and treatments received make it possible to estimate the diagnosis-related treatment costs, but estimates of the health gain that results from these interventions are missing. A method to estimate the likely health gain attributable to an intervention was developed by Andrews et al (Reference Andrews, Sanderson and Corry2000) and Sanderson et al (Reference Sanderson, Andrews and Corry2004). Using data from the Australian mental health surveys, they examined the cost-effectiveness of current and optimal treatments for schizophrenia (Reference Andrews, Sanderson and CorryAndrews et al, 2003a ), affective disorders (Reference Sanderson, Andrews and CorrySanderson et al, 2003), anxiety disorders (Reference Issakidis, Sanderson and CorryIssakidis et al, 2004) and alcohol use disorders (Reference Corry, Sanderson and IssakidisCorry et al, 2004) and concluded that optimal treatment was uniformly more cost-effective than current treatment. The present paper summarises these findings to assess the relative efficiency of treatment across these disorders, then calculates the cost-effectiveness of optimal treatment at optimal coverage and, finally, estimates the proportion of the burden of mental disorders that appears to be unavertable in the light of current knowledge.

METHOD

The general method for these studies is given in Andrews et al (Reference Andrews, Sanderson and Corry2003a ) and a summary is presented here. The general assumptions, and the evidence for them, are listed in Table 1.

Table 1 Assumptions and justifications used in modelling

Assumption	Justification
(1) A 1-year time horizon was used to estimate the years lived with disability (YLDs) averted with treatment as well as the costs of the treatment	This project was examining the total 1-year expenditure on mental health-related treatment in Australia, so a 1-year time frame was appropriate. Also, efficacy was estimated from randomised controlled trials (RCTs) which rarely measure outcome beyond 1 year, and it is recommended that short and longer time horizons be modelled separately when the analysis must go beyond the time frame of the primary data (Reference Gold, Siegel and RussellGold et al, 1996)
(2) The YLDs can be attributed to harmful use of alcohol or alcohol dependence when a person identifies it as their principal complaint in the previous 12 months	Attributing YLDs to a person's self-identified principal complaint ensures that YLDs are not double-counted in the presence of comorbidity (Reference Andrews, Slade and IssakidisAndrews et al, 2002)
(3) Service use can be attributed to harmful use of alcohol or alcohol dependence when a person identifies it as their principal complaint in the previous 12 months	Attributing service use and associated costs to a person's self-identified principal complaint ensures that costs are not double-counted in the presence of comorbidity (Reference Andrews, Slade and IssakidisAndrews et al, 2002)
(4) For current treatment evidence-based interventions can be defined as cognitive-behavioural therapy, counselling or medication and two or more visits with a clinician	Randomised controlled trials support medication and psychological interventions as efficacious for alcohol use disorders (Reference Nathan and GormanNathan & Gorman, 2002). Two or more visits are presumed sufficient, as a minimum, for the provision of such interventions. The mean number of contacts actually ranged from three to seven for most health professional types
(5) It is reasonable to define optimal treatment by operationalising detailed clinical practice guidelines, meta-analyses and expert reviews	Clinical practice guidelines, meta-analyses and expert reviews summarise research and clinical expertise on optimal care for a disorder, and provide the best source for defining optimal care
(6) The real-world effectiveness of an intervention can be approximated from efficacy studies	Efficacy from RCTs includes those who did not complete the trial and noncompliance if an intent-to-treat analysis is used. For this analysis, treatment resistance was modelled for a proportion of cases, and thus the actual magnitude of effect applied at a population level lies somewhere between efficacy and effectiveness
(7) Individual health benefits can be reflected in population estimates of YLDs averted	Population health as measured by YLDs is an aggregation of individual health because YLDs are calculated from the prevalence of a disorder weighted by severity of disability in individuals. For this analysis YLDs were adjusted for time spent symptomatic by multiplying YLDs by the ratio of 12-month to 1-month cases
(8) The effect size captures both changes in severity and duration of illness used in YLD calculations	The effect size is a standardised mean difference, and summarises the overall benefit of those who improved and remitted and those who improved but not enough to remit. An overall effect size thus implicitly includes the benefit of remitted cases, which is equivalent to a reduced duration
(9) The degree of change in symptoms resulting from treatment (measured in effect size units) in clinical trials reflects the degree of change in disability weightings used in YLD calculations	Changes in health status preference values used for YLD calculations are rarely measured in clinical trials in psychiatry and no such trials exist for alcohol use disorders. Studies in psychiatry have indicated a close correspondence between symptoms and disability (e.g. Reference Ormel, Von Korff and Van den BrinkOrmel et al, 1993)
(10) Service use reported by individuals in representative population surveys is sufficiently accurate for bottom-up costing	Service use for this analysis was derived from the National Survey of Mental Health and Well-Being (Reference Andrews, Henderson and HallAndrews et al, 2001), which was a nationally representative population survey. Self-reported service use from epidemiological surveys is reasonably consistent with other sources of service use data, albeit slightly underestimated (Reference Manderscheid, Rae and NarrowManderscheid et al, 1993)

Sensitivity analyses

A sensitivity analysis conducted with @RISK version 4 software (Newfield, NY: Palisade Corporation) for Microsoft Excel provided confidence intervals around the YLDs averted, the total cost of treatment and the cost per YLD averted for each disorder and disorder group at current coverage. Multivariate stepwise linear regressions were conducted for each disorder to identify the important contributors to variance around the cost-effectiveness ratios, and univariate analyses assessed the impact of changing various investigator-modelled parameters on the cost-effectiveness estimates. Confidence intervals around the cost-effectiveness or efficiency estimates for current and optimal treatment are presented in Tables 2 and 3. The results of univariate modelling and regression analyses are reported in the disorder-specific papers.

Table 2 Cost-effectiveness of treatment given the current coverage and mix of interventions

	Population burden		Burden averted				Cost		Efficiency
	Prevalence	YLDs1	Coverage	Effective	YLDs averted		Cost per	Total cost	$/YLD	95% CI
	(n)	(n)	(%)	coverage (%)	(n)	(%)	case (AUS$)	(AUS$×106)	(AUS$)	(AUS$)
Any affective disorder	797 892	194 162	59.8	33.7	30 078	15	1290	615.5	20 463	12 885-36 552
Depression	648 375	143 0 18	60.2	31.7	22 559	16	1239	483.7	21 442	11 434-40 433
Dysthymia	78 209	37 781	50.9	33.3	4982	13	1779	70.8	14 217	6157-36 536
Bipolar disorder	71 308	13 363	66.1	46.2	2536	19	1294	60.9	24 031	11 079-93 844
Any anxiety disorder	1 086 331	20 1 547	35.2	19.7	26 059	13	1035	395.7	15 184	12 934-19 031
Panic disorder/agoraphobia	175 994	25 338	39.1	23.8	2375	9	1188	81.7	34 389	20 998-49 854
Social phobia	206 976	30 058	20.8	6.7	2530	8	1011	43.6	17 218	10 136-26 038
Generalised anxiety disorder	376 290	85 341	37.6	20.5	14 469	17	795	112.3	7761	5531-10 488
Post-traumatic stress disorder	327 071	60 810	39.5	25.1	6687	11	1224	158.2	23 656	17 148-41 932
Any alcohol use disorder	479 342	48 744	10.7	5.6	745	2	1417	72.9	97 932	51 158-183 203
Harmful use of alcohol	251 911	5304	8.1	3.6	95	2	449	9.2	96 813	56 407-30 1 262
Alcohol dependence	227 431	43 439	13.6	7.8	650	2	2056	63.7	98 095	45 335-197 999
Schizophrenia	39 048	28 671	100	100	3774	13	18 949	739.9	196 070	123 827-297 516
Any study mental disorder	2 402 613	473 123	39.5	22.8	60 655	13	1920	1824.0	30 072	25 424-38 303

Table 3 Cost-effectiveness of treatment given the current coverage and optimal treatment with evidence-based medicine

	Population burden		Burden averted				Cost		Efficiency
	Prevalence	YLDs1	Coverage	Effective cov-	YLDs averted		Cost per	Total cost	$/YLD	95% CI
	(n)	(n)	(%)	erage (%)	(n)	(%)	case (AUS$)	(AUS$×106)	(AUS$)	(AUS$)
Any affective disorder	797 892	194 162	59.8	59.8	44 557	23	1002	478.4	10 737	9103-13 896
Depression	648 375	143 0 18	60.2	60.2	32 583	23	874	341.3	10 475	8283-14 049
Dysthymia	78 209	37 781	50.9	50.9	7446	20	721	28.7	3858	3283-4983
Bipolar disorder	71 308	13 363	66.1	66.1	4529	34	2301	108.4	23 934	14 785-38 298
Any anxiety disorder	1 086 331	20 1 547	35.2	35.2	40 10 1	20	957	366.1	9130	7965-11 161
Panic disorder/agoraphobia	175 994	25 338	39.1	39.1	3304	13	953	65.4	19 820	13 221-28 087
Social phobia	206 976	30 058	20.8	20.8	3885	13	769	33.1	8531	5980-12 253
Generalised anxiety disorder	376 290	85 341	37.6	37.6	23 424	27	837	118.2	5048	4105-6116
Post-traumatic stress disorder	327 071	60 810	39.5	39.5	9489	16	1155	149.2	15 728	12 550-24 311
Any alcohol use disorder	479 342	48 744	10.7	10.7	2253	5	2338	120.3	53 412	27 007-92 283
Harmful use of alcohol	251 911	5304	8.1	8.1	191	4	83	1.7	8861	5202-9360
Alcohol dependence	227 431	43 439	13.6	13.6	2061	5	3827	118.6	57 542	28 220-102 397
Schizophrenia	39 048	28 671	100	100	6217	22	17 113	668.2	107 482	59 714-205 418
Any study mental disorder	2 402 613	473 123	39.5	39.5	93 128	20	1719	1633.1	17 536	16 132-20 145

RESULTS

In Table 1 we present the assumptions that underlie this set of studies. In Table 2 we present the results for the current situation in Australia using data that appear in each of the individual papers for each of the ten mental disorders studied and for the four disorder groups. In the present paper we provide additional estimates summed across all ten mental disorders. Data are tabulated by diagnostic group, by the estimated numbers of cases in the population and by the estimated total YLDs that would be lost in the absence of treatment in the Australian population. Next in the table are data on the percentage coverage, percentage effective or evidence-based medicine coverage and absolute number and percentage of YLDs averted. Lastly, there are data on the average cost per case, the total cost and the efficiency (including confidence intervals) in 1997 Australian dollars per YLD averted, again by the various diagnostic groupings. Only a proportion of people who met the criteria for an ICD–10 mental disorder reported receiving an evidence-based intervention.

The current mix of coverage and interventions was estimated to reach two-fifths of cases, although only one-fifth received a potentially effective treatment. The remaining cases were presumed to generate a treatment cost but no benefit. This mix of interventions was estimated to avert some 61 000 YLDs, which is one-eighth of the YLDs attributed to these mental disorders. About one-fifth of the burden of bipolar disorder was deemed to be averted by effective treatment, whereas only one-fiftieth of the burden of alcohol use disorders was averted, in part owing to the very low rate of effective coverage. The total cost of current interventions was AUS$1800 million, with the cost per case of schizophrenia being ten times the average.

In Table 3 we present data for optimal treatment, that is, patients are expected to receive optimal or evidence-based treatment, now defined and costed on the basis of established guidelines. Coverage and severity are held at the same level as in Table 2. Effective coverage is deemed to reach two-fifths of people with mental disorders and the replacement of ineffective with effective treatment results in an extra 30 000 YLDs being averted, so one-fifth of the YLDs attributed to these mental disorders could be averted. One-third of the burden of bipolar disorder was deemed to be averted by effective treatment, whereas only one-twentieth of the burden of alcohol use disorders was averted, again in part owing to the very low rate of effective coverage.

The total cost of an optimal treatment that included more therapies was AUS$1600 million, which is close to the cost of current treatment, principally because of a reduction in in-patient stays recommended by the clinical practice guidelines. Treatment of schizophrenia was still ten times the average cost per case. The average cost-effectiveness was AUS$18 000 per YLD gained. On average, the cost of providing evidence-based medicine to the people currently seeking treatment is within the present budget.

In Table 4 we present data for optimal treatment, but now coverage is increased to practical levels as defined in the method, and severity is assumed to reflect that among those in treatment as well as those who are not currently in contact with services. Coverage overall is now two-thirds, and in this situation 28% of the burden could be averted at a cost-effectiveness ratio of AUS$16 000 per YLD averted. The total cost rises by some AUS$300 million over the current level of expenditure on these disorders.

Table 4 Cost-effectiveness of treatment given optimal coverage and optimal treatment with evidence-based medicine

	Population burden		Burden averted				Cost		Efficiency
	Prevalence	YLDs1	Coverage	Effective	YLDs averted		Cost per case	Total cost	$/YLD
	(n)	(n)	(%)	coverage (%)	(n)	(%)	(AUS$)	(AUS$×106)	(AUS$)
Any affective disorder	797 892	194 162	70	70	52 176	27	941	525.7	10 075
Depression	648 375	143 0 18	70	70	37 518	26	827	375.5	10 0 10
Dysthymia	78 209	37 781	70	70	10 032	27	645	35.3	3517
Bipolar disorder	71 308	13 363	70	70	4626	35	2301	114.8	24 827
Any anxiety disorder	1 086 331	20 1 547	70	70	70 784	35	1754	670.8	9476
Panic disorder/agoraphobia	175 994	25 338	70	70	5244	21	916	112.8	21 518
Social phobia	206 976	30 058	70	70	10 20 1	34	764	110.7	10 851
Generalised anxiety disorder	376 290	85 341	70	70	40 981	48	779	205.1	5004
Post-traumatic stress disorder	327 071	60 810	70	70	14 358	24	1058	242.2	16 867
Any alcohol use disorder	479 342	48 744	51	51	5597	11	1054	257.8	46 064
Harmful use of alcohol	251 911	5304	70	70	1059	20	83	14.6	13 775
Alcohol dependence	227 431	43 439	30	30	4537	10	3565	243.2	53 603
Schizophrenia	39 048	28 671	100	100	6217	22	17 113	668.2	107 482
Any study mental disorder	2 402 613	473 123	67	67	134 774	28	1324	2122.5	15 748

In Table 5 we present data that presume the impossible situation of perfect coverage and complete evidence-based medicine, simply to show the proportion of mental disorder burden that could be averted and, as a corollary, the proportion that is unavertable given current knowledge. On average only two-fifths of the burden appears to be avertable within the limits of current best practices in mental health. The most optimistic finding is that two-thirds of the burden of generalised anxiety disorder is theoretically avertable; the most pessimistic finding is that only one-fifth of the burden of schizophrenia is avertable. Three-fifths of the burden of mental disorders therefore remains unavertable, which is a sobering fact about the limitations of current knowledge in psychiatry but one that is consistent with clinical practice.

Table 5 Cost-effectiveness of treatment given 100% coverage and optimal treatment with evidence-based medicine

	Population burden		Burden averted
	Prevalence	YLDs	Coverage	Effective coverage	YLDs averted
	(n)	(n)	(%)	(%)	(n)	(%)
Any affective disorder	797 892	194 162	100	100	67 715	35
Depression	648 375	143 0 18	100	100	48 239	34
Dysthymia	78 209	37 781	100	100	14 105	37
Bipolar disorder	71 308	13 363	100	100	5372	40
Any anxiety disorder	1 086 331	20 1 547	100	100	98 390	49
Panic disorder/agoraphobia	175 994	25 338	100	100	7090	28
Social phobia	206 976	30 058	100	100	14 798	49
Generalised anxiety disorder	376 290	85 341	100	100	57 213	67
Post-traumatic stress disorder	327 071	60 810	100	100	19 289	32
Any alcohol use disorder	479 342	48 744	100	100	16 603	34
Harmful use of alcohol	251 911	5304	100	100	1479	28
Alcohol dependence	227 431	43 439	100	100	15 124	35
Schizophrenia	39 048	28 671	100	100	6217	22
Any study mental disorder	2 402 613	473 123	100	100	188 926	40

DISCUSSION

This was a modelling exercise based on good epidemiological data. The summary results are that optimal treatment would avert a greater proportion of the burden of mental disorders and, even though more comprehensive, would cost no more than current treatment because of fewer in-patient stays and no use of treatments that generated costs but no benefits. Because all treatment was deemed to generate benefit, we should implement clinical practice guidelines for the treatment of mental disorders, despite resistance from the profession (Reference AndrewsAndrews, 1999). The costs presented are the direct treatment costs, sometimes equated to those of the government or provider perspective. Like many others, we have shown elsewhere that the indirect costs of illness are five or more times greater than the direct treatment costs (Reference Andrews, Hall and GoldsteinAndrews et al, 1985). By not including these costs we may have underestimated the wider costs of disorders in current care, as well as the potential cost reductions under optimal care. Whether the ratios of indirect to direct costs are likely to differ by disorder is beyond the scope of this paper.

The present findings suggest that even if everyone was treated in the best possible fashion, about 60% of the burden of mental disorders appears to be unavertable in the light of current knowledge. Throughout all calculations about current, optimal or targeted optimal (Tables 2, 3, 4), the treatment of schizophrenia costs significantly more than the treatment of the other disorders. It is difficult to express the cost-effectiveness in other currencies simply because the unit costs are based on prices paid for services in Australia in 1997 and the prices in other countries can be markedly different. The strength of the present set of calculations is the ability to compare the cost of current and optimal treatment across the ten disorders, a relationship that may well apply in other countries. The cost of one unit of health gain in schizophrenia seems likely to be an order of magnitude greater than the cost of one unit of health gain in anxiety or depressive disorders, whatever the currency involved.

The limitations of this series of studies are many. Although the surveys from which the data are derived are good, it must be remembered that the data are based on self-reported symptoms to establish diagnosis and self-reported treatments to establish costs. The threshold for the proportion of people currently receiving evidence-based medicine in Table 2 is optimistic (‘two visits from the same professional and the receipt of medication or cognitive–behavioural therapy’) and a stricter definition would have resulted in less efficiency and less burden averted. Nevertheless, few patients reported the minimum of two visits, with seven visits to a general practitioner being the mean and additional visits of the same frequency being reported to psychiatrists or psychologists. Optimal treatment, as costed in Tables 3, 4, 5, incorporated the recommendations of clinical practice guidelines and their operationalisation by the investigators, both of which may be imperfect. Adherence, calculated from the results of intention-to-treat analyses in randomised controlled trials, even compensated by our inclusion of treatment-resistant groups, may overestimate the real situation. The present data are therefore optimistic, but to correct for these biases would require data that do not exist.

A number of other diagnoses were identified in the surveys. Data on obsessive–compulsive disorder, drug use disorders and neurasthenia were not included because of the small numbers of people identifying these disorders as their principal complaint. Data on personality disorders were not included because of the lack of evidence-based guidelines for treatment. Nevertheless, the four disorder groups studied represent 80% of the identified costs of treatment for mental disorders. This study has a 1-year time horizon and there is evidence that a longer time horizon might have shown a greater proportion of burden able to be averted. But because the data for all disorders were only available for the 1-year period, and the evidence about burden averted in the longer term is only available for depression, this is a necessary limitation. The method to estimate YLDs averted from effect sizes is new, and although the magnitude of change is consistent with the few studies in mental health that have measured changes in symptoms and health state preference values (e.g. Reference Hatziandreu, Brown and RevickiHatziandreu et al, 1994; Reference Lonnqvist, Sintonen and SyvalahtiLonnqvist et al, 1994), the method would benefit from replication. The confidence intervals are wide, reflecting uncertainty in some parts of the analysis, but even so the confidence intervals around some interventions, especially those for schizophrenia, indicate that differences in efficiency between some disorders are real.

The strength of the study is that it is based on two population surveys that have the capacity to provide a view of health service efficiency in Australia around 1997. Assumptions allow the cost and effectiveness of evidence-based medicine to be examined. Importantly, the method will allow replication in other data-sets as well as comparison with the cost-effectiveness of current and optimal treatment for a number of physical disorders. Current work is under way to compare these results with three physical disorders chosen to resemble mental disorders in prevalence, burden and natural history.

The results in Tables 2, 3, 4, 5 are displayed according to the burden presently averted, the burden averted by improvement in intervention and coverage and the burden unavertable in the light of existing knowledge. We would like to review these results, commenting on each of the disorders in turn.

1. (a) Affective disorders. Current coverage is 60%, with about half of those with affective disorders receiving medication or cognitive–behavioural therapy. Fifteen per cent of the burden is averted, at an average cost of AUS$20 000 per YLD. When all receive treatment according to the clinical practice guidelines, the burden averted climbs to 23% at an average of AUS$11 000 per YLD. The gratifying result is that coverage of bipolar disorder is nearly optimal and that evidence-based medicine could avert one-third of the burden of that disorder at reasonable cost. Optimal treatment for the affective disorders is cost-effective, and that for dysthymia (at AUS$4000 per YLD) is especially so.

2. (b) Anxiety disorders. Current coverage is low, too low for what are the most treatable disorders, with, for example, only 7% of people with social phobia receiving notionally effective treatment. We do not know why coverage is so low: these patients identified anxiety as their principal complaint and treatment with selective serotonin reuptake inhibitors is not difficult. Increasing the coverage to 70%, with all getting evidence-based medicine, changes the picture. One-third of the burden is averted (half of the burden in generalised anxiety disorder) at an average cost of AUS$9000 per DALY. Nevertheless, even with perfect coverage and treatment, half the burden of anxiety disorders would remain unavertable (Table 5).

3. (c) Alcohol use disorders. Coverage, at 11%, is appalling. Only 2% of the burden is averted and, at AUS$97 000 per YLD, efficiency is low, not because the cost per case is especially high but because the calculated healthgain is low. Increasing the coverage of interventions for harmful use to 70% and for dependence to 30% would result in one-ninth of the burden being averted, but the average cost per YLD remains high. Nevertheless, a campaign to encourage recognition and brief intervention in primary care for cases of harmful use may well be a sensible investment of funds, given the potential efficiency of AUS$14 000 per YLD gained for such a treatment. On the other hand, evidence-based medicine for alcohol dependence is costly, even though in-patient detoxification was considered only for people with hallucinations or seizures in our model.

4. (d) Schizophrenia. Coverage of schizophrenia was deemed to be complete because the data were obtained from catchment area studies in which every effort was made to identify all cases in contact with any of a wide range of services. We have argued elsewhere that there are probably an additional 10–20% of undiagnosed cases in the community (Reference Andrews, Sanderson and CorryAndrews et al, 2003a ) but for the purposes of this exercise we have accepted the coverage at a notional 100%. Current treatment with effective agents relieves 13% of the burden at a cost close to AUS$200 000 per YLD gained, due in part to the high cost per case. The sampling strategy for this group was different from that for the other disorders and may have resulted in a scarcity of milder cases. Even so, it is unlikely that the inclusion of such people would increase the efficiency of treatment or the burden averted to levels comparable with the other disorders. Schizophrenia is an expensive disease, a fact that has been known for some time (Reference Andrews, Hall and GoldsteinAndrews et al, 1985). Adoption of clinical practice guidelines could increase the proportion of YLDs averted to 22%, but the cost per YLD would still remain somewhere between AUS$60 000 and AUS$205 000. It would be important to examine the detail of this expenditure to determine whether the same clinical outcome could be achieved with less use of the high-cost elements, giving greater efficiency overall. Nevertheless, there are societal and humanitarian needs that make the treatment of schizophrenia imperative, no matter what the cost (see discussion in Reference Andrews, Sanderson and CorryAndrews et al, 2003a ).

It would be simple to look at these results and argue for a health system that would return the greatest health gain for the least money. Certainly we would recommend that the coverage of anxiety and depressive disorders be increased, given that treatment is so cost-effective. Given the affordability of evidence-based treatment we would recommend that clinicians be encouraged to practise evidence-based medicine, even if the budgetary and organisational requirements of implementation are considerable. However, setting priorities for service delivery is about equity, need and societal demand, as well as about efficiency (Reference CalmanCalman, 1994; Reference Callahan, Boyle and CallahanCallahan, 1995). Although there is extensive consideration of the tension between these elements in the literature, there is little consensus as to how they should be operationalised or whether such priority setting should be implicit or explicit (Reference MusgroveMusgrove, 1999; Reference RosenheckRosenheck, 1999; Reference JackJack, 2000). Moreover, the existence of a hierarchical relationship among the grounds thought to justify public expenditure is also widely debated (Reference MaynardMaynard, 1999; Reference MusgroveMusgrove, 1999; Reference RosenheckRosenheck, 1999). A detailed analysis of these questions is warranted, but is best reserved until the present results have been discussed and the benefits and gains of each element in the treatment process carefully assessed (see Reference GoldbergGoldberg, 2003; Reference WarnerWarner, 2003; Reference Haby, Carter and MihalopolousHaby et al, 2004). In the meantime, the high cost of schizophrenia (AUS$200 000 per YLD) is a signal that cannot be ignored. We need to invest serious money into research on the mechanism behind this disease, exactly as we are doing for Alzheimer's disease, and did for HIV/AIDS. Further, given that 60% of the burden of mental disorders appears to be unavertable with current knowledge, it would be reasonable to conclude that further research into both the prevention and the mechanisms of these diseases is required.

Clinical Implications and Limitations